| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.1 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.29 | 0.1 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.1 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |